It does look interesting. That third segment of virtually no revenue in medical marijuana looks like a good wild card. All those partnerships signed near the end of March or early April. And approval to for prescriptions, which they can sell in their own clinics and all those partners in Columbia and Peru, etc. That could prove to be a dramatic increase in revenue very soon. Helping their health clinic and the marijuana segment. Very dramatically in theory. It could become a reality. If all goes well, they'll have the revenue next year that HLIX has now.
To heck with Kuida, although they have long term potential there. And they are good optics. I do like the marketing there and the potential of other product lines in teh future. It's so tiny right now though. Only 6 thousand units sold, but big revenue for only 6,000 units. Sell 80,000 units at this rip-off prices, and it starts to look pretty good. And women will pay! They love to pay exhorbitant fees for stuff like that. And the pre-covid educational kiosks. Those are great! Placebo or not, they'll believe. Good expensive retail shops to carry it. It's good money they are burning there for now.
It does indeed seem like their CapEx pending is finished for the most part. It seems on the surface.
I would say HLIX cares about their shareholders too. There is also an interesting clip from Fox in the last 3 minutes from Vincente Fox here on Khiron. That insistence in principles would carry over to HLIX:
The financing they have furthers the case that HLIX should be able to get something big as they do have better numbers currently. They do need major consolidation.
They do have a lot of cash at Khiron, but like KERN, they are going to be out of cash by this time next year. HLIX is really close to profitability already, so I think you are going to see something big on the financing end coming up soon for HLIX. Just common sense comparing the fundamentals of those 3.
I do like Khiron though. I think HLIX is a better value right now. Khiron, if that medical marijuana segment is explosive, and it could very well be, it might be a decent speculative value price right now. I'd want a foot in the door at least there. It's good that it's down like the whole industry. It seems like they bought back some of their stock at .30 cents, and cancelled it, which is what their investors paid $2.50 ish for. That's a good deal! For them and for shareholders. Perhaps not for the initial investors. I'll give you 15 cents for your dollar! Thank you very much! I like it. It' better to buy Khiron here than it was to give them the funding. Even with those warrants. It's still not cheap based on today's revenue. But it's decent value if they really ramp things up it seems, and there are indeed some big things in the pipeline. And it's real. I do like it.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.